MicroRNA-33b, upregulated by EF24, a curcumin analog, suppresses the epithelial-to-mesenchymal transition (EMT) and migratory potential of melanoma cells by targeting HMGA2

Toxicology Letters

Volumn 234, Issue 3, 2015, Pages 151-161

  Zhang, Pu ^a,b   Bai, Huiyuan ^a   Liu, Gentao ^c   Wang, Heyong ^c   Chen, Feng ^a   Zhang, Baoshun ^a   Zeng, Panying ^a   Wu, Chengxiang ^a   Peng, Cong ^a   Huang, Changjin ^d,e   Song, Yang ^a   Song, Erqun ^a  

^a SOUTHWEST UNIVERSITY   (China)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cancer migration; EF24; EMT; HMGA2; Melanoma; MiR 33b

Indexed keywords

3,5 BIS(2 FLUOROBENZYLIDENE) 4 PIPERIDINONE; ACTIN; FOCAL ADHESION KINASE; HIGH MOBILITY GROUP A2 PROTEIN; MICRORNA; MICRORNA 33B; NERVE CELL ADHESION MOLECULE; PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SRC PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; 3,5-BIS(2-FLUOROBENZYLIDENE)PIPERIDIN-4-ONE; ANTINEOPLASTIC AGENT; BENZYLIDENE DERIVATIVE; CURCUMIN; MIRN33 MICRORNA, HUMAN; PIPERIDONE DERIVATIVE;

3' UNTRANSLATED REGION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; FOCAL ADHESION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL LINE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; ANALOGS AND DERIVATIVES; CELL MOTION; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BENZYLIDENE COMPOUNDS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CURCUMIN; EPITHELIAL-MESENCHYMAL TRANSITION; FLUORESCENT ANTIBODY TECHNIQUE; HMGA2 PROTEIN; HUMANS; MELANOMA; MICRORNAS; PIPERIDONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 84924069193     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2015.02.018     Document Type: Article

References (51)

1. Adams B.K., Cai J., Armstrong J., Herold M., Lu Y.J., Sun A., Snyder J.P., Liotta D.C., Jones D.P., Shoji M. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anti-Cancer Drugs 2005, 16:263-275.
2. Adams B.K., Ferstl E.M., Davis M.C., Herold M., Kurtkaya S., Camalier R.F., Hollingshead M.G., Kaur G., Sausville E.A., Rickles F.R., Snyder J.P., Liotta D.C., Shoji M. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg. Med. Chem. 2004, 12:3871-3883.
3. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
4. Bao B., Ali S., Banerjee S., Wang Z., Logna F., Azmi A.S., Kong D., Ahmad A., Li Y., Padhye S., Sarkar F.H. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res. 2012, 72:335-345.
5. Baranwal S., Alahari S.K. miRNA control of tumor cell invasion and metastasis. Int. J. Cancer J. Int. du Cancer 2010, 126:1283-1290.
6. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
7. Brown M.C., Turner C.E. Paxillin: adapting to change. Physiol. Rev. 2004, 84:1315-1339.
8. Bushati N., Cohen S.M. microRNA functions. Annu. Rev. Cell Dev. Biol. 2007, 23:175-205.
9. Chen H.W., Lee J.Y., Huang J.Y., Wang C.C., Chen W.J., Su S.F., Huang C.W., Ho C.C., Chen J.J., Tsai M.F., Yu S.L., Yang P.C. Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res. 2008, 68:7428-7438.
10. Cheng C.J., Bahal R., Babar I.A., Pincus Z., Barrera F., Liu C., Svoronos A., Braddock D.T., Glazer P.M., Engelman D.M., Saltzman W.M., Slack F.J. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 2014.
11. Chudnovsky Y., Khavari P.A., Adams A.E. Melanoma genetics and the development of rational therapeutics. J. Clin. Invest. 2005, 115:813-824.
12. Davalos A., Goedeke L., Smibert P., Ramirez C.M., Warrier N.P., Andreo U., Cirera-Salinas D., Rayner K., Suresh U., Pastor-Pareja J.C., Esplugues E., Fisher E.A., Penalva L.O., Moore K.J., Suarez Y., Lai E.C., Fernandez-Hernando C. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:9232-9237.
13. Dong H., Xu D., Hu L., Li L., Song E., Song Y. Evaluation of N-acetyl-cysteine against tetrachlorobenzoquinone-induced genotoxicity and oxidative stress in HepG2 cells. Food Chem. Toxicol. 2014, 64:291-297.
14. Fusco A., Fedele M. Roles of HMGA proteins in cancer. Nat. Rev. Cancer 2007, 7:899-910.
15. Gerin I., Clerbaux L.A., Haumont O., Lanthier N., Das A.K., Burant C.F., Leclercq I.A., MacDougald O.A., Bommer G.T. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J. Biol. Chem. 2010, 285:33652-33661.
16. Goedeke L., Vales-Lara F.M., Fenstermaker M., Cirera-Salinas D., Chamorro-Jorganes A., Ramirez C.M., Mattison J.A., de Cabo R., Suarez Y., Fernandez-Hernando C. A regulatory role for microRNA 33* in controlling lipid metabolism gene expression. Mol. Cell. Biol. 2013, 33:2339-2352.
17. Guo L., Chen C., Shi M., Wang F., Chen X., Diao D., Hu M., Yu M., Qian L., Guo N. Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition. Oncogene 2013, 32:5272-5282.
18. Huh S.J., Liang S., Sharma A., Dong C., Robertson G.P. Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res. 2010, 70:6071-6082.
19. Jaksik R., Lalik A., Skonieczna M., Cieslar-Pobuda A., Student S., Rzeszowska-Wolny J. MicroRNAs and reactive oxygen species: are they in the same regulatory circuit?. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 2014, 764-765:64-71.
20. Kanai M. Therapeutic applications of curcumin for patients with pancreatic cancer. World J. Gastroenterol.: WJG 2014, 20:9384-9391.
21. Kasinski A.L., Du Y., Thomas S.L., Zhao J., Sun S.Y., Khuri F.R., Wang C.Y., Shoji M., Sun A., Snyder J.P., Liotta D., Fu H. Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene) piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol. Pharmacol. 2008, 74:654-661.
22. Kedde M., Strasser M.J., Boldajipour B., Oude Vrielink J.A., Slanchev K., le Sage C., Nagel R., Voorhoeve P.M., van Duijse J., Orom U.A., Lund A.H., Perrakis A., Raz E., Agami R. RNA-binding protein Dnd1 inhibits microRNA access to target mRNA. Cell 2007, 131:1273-1286.
23. Kloosterman W.P., Plasterk R.H. The diverse functions of microRNAs in animal development and disease. Dev. Cell 2006, 11:441-450.
24. Kronski E., Fiori M.E., Barbieri O., Astigiano S., Mirisola V., Killian P.H., Bruno A., Pagani A., Rovera F., Pfeffer U., Sommerhoff C.P., Noonan D.M., Nerlich A.G., Fontana L., Bachmeier B.E. miR181b is induced by the chemopreventive polyphenol curcumin and inhibits breast cancer metastasis via down-regulation of the inflammatory cytokines CXCL1 and -2. Mol. Oncol. 2014, 8:581-595.
25. Lai E.C. Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat. Genet. 2002, 30:363-364.
26. Liang S., Sharma A., Peng H.H., Robertson G., Dong C. Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res. 2007, 67:5814-5820.
27. Liang Y., Zheng T., Song R., Wang J., Yin D., Wang L., Liu H., Tian L., Fang X., Meng X., Jiang H., Liu J., Liu L. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1alpha inhibition in hepatocellular carcinoma. Hepatology 2013, 57:1847-1857.
28. Ling M., Li Y., Xu Y., Pang Y., Shen L., Jiang R., Zhao Y., Yang X., Zhang J., Zhou J., Wang X., Liu Q. Regulation of miRNA-21 by reactive oxygen species-activated ERK/NF-kappaB in arsenite-induced cell transformation. Free Radical Biol. Med. 2012, 52:1508-1518.
29. Liu H., Liang Y., Wang L., Tian L., Song R., Han T., Pan S., Liu L. In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcumin analog. PLoS One 2012, 7:e48075.
30. Ma J., Fang B., Zeng F., Pang H., Zhang J., Shi Y., Wu X., Cheng L., Ma C., Xia J., Wang Z. Curcumin inhibits cell growth and invasion through up-regulation of miR-7 in pancreatic cancer cells. Toxicol. Lett. 2014, 231:82-91.
31. Mitra S.K., Hanson D.A., Schlaepfer D.D. Focal adhesion kinase: in command and control of cell motility. Nat. Rev. Mol. Cell Biol. 2005, 6:56-68.
32. Mudduluru G., George-William J.N., Muppala S., Asangani I.A., Kumarswamy R., Nelson L.D., Allgayer H. Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer. Biosci. Rep. 2011, 31:185-197.
33. Pencheva N., Tavazoie S.F. Control of metastatic progression by microRNA regulatory networks. Nat. Cell Biol. 2013, 15:546-554.
34. Reid J.M., Buhrow S.A., Gilbert J.A., Jia L., Shoji M., Snyder J.P., Ames M.M. Mouse pharmacokinetics and metabolism of the curcumin analog, 4-piperidinone, 3,5-bis[(2-fluorophenyl) methylene]-acetate(3E,5E) (EF-24; NSC 716,993). Cancer Chemother. Pharmacol. 2014, 73:1137-1146.
35. Rice S.J., Lai S.C., Wood L.W., Helsley K.R., Runkle E.A., Winslow M.M., Mu D. MicroRNA-33a mediates the regulation of high mobility group AT-hook 2 gene (HMGA2) by thyroid transcription factor 1 (TTF-1/NKX2-1). J. Biol. Chem. 2013, 288:16348-16360.
36. Rokavec M., Oner M.G., Li H., Jackstadt R., Jiang L., Lodygin D., Kaller M., Horst D., Ziegler P.K., Schwitalla S., Slotta-Huspenina J., Bader F.G., Greten F.R., Hermeking H. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J. Clin. Invest. 2014, 124:1853-1867.
37. Saini S., Arora S., Majid S., Shahryari V., Chen Y., Deng G., Yamamura S., Ueno K., Dahiya R. Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev. Res. 2011, 4:1698-1709.
38. Scherr M., Venturini L., Battmer K., Schaller-Schoenitz M., Schaefer D., Dallmann I., Ganser A., Eder M. Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Res. 2007, 35:e149.
39. Seo J.H., Jeong K.J., Oh W.J., Sul H.J., Sohn J.S., Kim Y.K., Cho do Y., Kang J.K., Park C.G., Lee H.Y. Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin. Cancer Lett. 2010, 288:50-56.
40. Soengas M.S., Lowe S.W. Apoptosis and melanoma chemoresistance. Oncogene 2003, 22:3138-3151.
41. Subramaniam D., May R., Sureban S.M., Lee K.B., George R., Kuppusamy P., Ramanujam R.P., Hideg K., Dieckgraefe B.K., Houchen C.W., Anant S. Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity. Cancer Res. 2008, 68:1962-1969.
42. Sun M., Gomes S., Chen P., Frankenberger C.A., Sankarasharma D., Chung C.H., Chada K.K., Rosner M.R. RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2. Oncogene 2014, 33:3528-3537.
43. Thomas S.L., Zhong D., Zhou W., Malik S., Liotta D., Snyder J.P., Hamel E., Giannakakou P. EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle 2008, 7:2409-2417.
44. Xu D., Hu L., Su C., Xia X., Zhang P., Fu J., Wang W., Xu D., Du H., Hu Q., Song E., Song Y. Tetrachloro-p-benzoquinone induces hepatic oxidative damage and inflammatory response, but not apoptosis in mouse: the prevention of curcumin. Toxicol. Appl. Pharmacol. 2014, 280:305-313.
45. Yang C.H., Yue J., Sims M., Pfeffer L.M. The curcumin analog EF24 targets NF-kappaB and miRNA-21, and has potent anticancer activity in vitro and in vivo. PloS One 2013, 8:e71130.
46. Yu T., Ji J., Guo Y.L. MST1 activation by curcumin mediates JNK activation, Foxo3a nuclear translocation and apoptosis in melanoma cells. Biochem. Biophys. Res. Commun. 2013, 441:53-58.
47. Yun J., Frankenberger C.A., Kuo W.L., Boelens M.C., Eves E.M., Cheng N., Liang H., Li W.H., Ishwaran H., Minn A.J., Rosner M.R. Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. EMBO J. 2011, 30:4500-4514.
48. Zeng Y., Cullen B.R. Sequence requirements for micro RNA processing and function in human cells. RNA 2003, 9:112-123.
49. Zhang P., Fu C., Bai H., Song E., Song Y. CD44 variant, but not standard CD44 isoforms, mediate disassembly of endothelial VE-cadherin junction on metastatic melanoma cells. FEBS Lett. 2014, 588:4573-4582.
50. Zhang P., Ozdemir T., Chung C.Y., Robertson G.P., Dong C. Sequential binding of alphaVbeta3 and ICAM-1 determines fibrin-mediated melanoma capture and stable adhesion to CD11b/CD18 on neutrophils. J. Immunol. 2011, 186:242-254.
51. Zhang Y., Yang P., Sun T., Li D., Xu X., Rui Y., Li C., Chong M., Ibrahim T., Mercatali L., Amadori D., Lu X., Xie D., Li Q.J., Wang X.F. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat. Cell Biol. 2013, 15:284-294.